by Scott Larrivee | Jun 26, 2025 | News
The following is a copy of a press release issued by Cellectar Biosciences Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for...
by Scott Larrivee | Jun 19, 2025 | News
Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
by Scott Larrivee | Jun 17, 2025 | News
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...
by Scott Larrivee | Jun 10, 2025 | News
Domestic stable isotope program key to stabilizing supply chains, enabling innovation WEST VALLEY CITY, Utah – June 10, 2025 – Nusano today announced it has successfully enriched gadolinium-160 (Gd-160) to 99.2% purity, a significant milestone demonstrating the...
by Scott Larrivee | Jun 10, 2025 | Utah
By Jessica Budin On June 9, 2025, Nusano welcomed more than 75 VIPs from throughout Utah for a preview of our new production facility. Attendees included government officials, local media outlets, university staff, trade associations, and customers. Nusano’s CEO...
